Thromboxane A2 and Osteoarthritis

Recruiting Observational Study
Osteoarthritis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
40 and older
Sex
Any
Study type
Observational
Participants needed
20 (estimated)
Sponsor
Centre Hospitalier Universitaire de Nice · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
TXA2 inhibits the expression of the primary marker of thermogenesis (UCP1) while prostacyclin (PGI2), another metabolite derived from arachidonic acid, enhances its expression. Given the close relationship between the adipocyte and the chondrocyte, the study team hypothesises that thromboxane A2 controls chondrocyte formation and function and thus cartilage homeostasis. The study objectives are: i…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * presence of knee osteoarthritis with effusion, , no inflammatory disease Exclusion Criteria: * anticoagulant treatment * inflammatory disease
Contacts

Christian ROUX, MD, PhD

+33492035491

roux.c2@chu-nice.fr

CONTACT